Sonoma Biotherapeutics
Nadia joins Sonoma Biotherapeutics with experience managing clinical contracting, outsourcing, and vendor management. She was most recently a manager at FibroGen focusing on contracting for Phase II-IV clinical trials. Prior to moving back to the Bay Area from Washington D.C., she held positions at organizations such as The Brand USA, Goldman Sachs, and Bio Ventures for Global Health. In those roles, her responsibilities included helping to build out teams and establish organizational processes.
Nadia holds a B.A. in Political Science from the University of California, Davis.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.